Investors

Overview

Corporate Profile

Gamida Cell is an advanced cell therapy company committed to finding cures for patients with blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Latest News

View All
Oct 13, 2020

Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration

Read More
Oct 07, 2020

Gamida Cell to Present at 2020 Virtual Cell & Gene Meeting on the Mesa

Read More
Oct 06, 2020

Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel in Patients with Hematologic Malignancies

Read More
Sep 10, 2020

Gamida Cell Presents Analysis of Observational Data Demonstrating the Impact of Donor Age in Hematopoietic Stem Cell Transplant Outcomes at the Virtual Cord Blood Connect Meeting

Read More
Sep 08, 2020

Gamida Cell to Participate in Upcoming Investor Conferences

Read More
Sep 03, 2020

Gamida Cell Announces Two-Part Virtual Miniseries Focused on Omidubicel to Take Place in September

Read More
Aug 17, 2020

Gamida Cell to Provide Webcast of Its Annual Meeting of Stockholders

Read More
Aug 11, 2020

Gamida Cell Reports Second Quarter 2020 Financial Results and Provides Company Update

Read More
Aug 04, 2020

Gamida Cell Announces the Date of Its Second Quarter 2020 Financial Results and Webcast

Read More
Jul 21, 2020

Gamida Cell Announces Appointment of Michele Korfin as Chief Operating and Chief Commercial Officer

Read More
Jul 07, 2020

Gamida Cell Announces Appointment of David Fox to Its Board of Directors

Read More
Jun 12, 2020

Gamida Cell to Present at the JMP Securities Virtual Hematology and Oncology Forum

Read More
May 26, 2020

Gamida Cell Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

Read More
May 21, 2020

Gamida Cell Reports First Quarter 2020 Financial Results and Provides Company Update

Read More
May 18, 2020

Gamida Cell Announces Pricing of $60 Million Public Offering of Ordinary Shares

Read More
May 18, 2020

Gamida Cell Announces Launch of Proposed Public Offering of Ordinary Shares

Read More
May 18, 2020

Gamida Cell Announces the Date of Its First Quarter 2020 Financial Results and Webcast

Read More
May 12, 2020

Gamida Cell Announces Positive Topline Data from Phase 3 Clinical Study of Omidubicel in Patients with High-Risk Hematologic Malignancies

Read More
Mar 02, 2020

Gamida Cell Announces Updated Data from Phase 1 Study of GDA-201 to be Presented at the Annual Meeting of the European Society for Blood and Marrow Transplantation

Read More
Feb 25, 2020

Gamida Cell Reports Full Year 2019 Financial Results and Provides Company Update

Read More
Upcoming Events
More events are coming soon.
Recent Events
Corporate Fact Sheet
Corporate Presentation

Investor & Media Contact

Jaren Irene Madden
Vice President of Investor Relations and Corporate Communications
Gamida Cell Ltd.
IRPR@gamida-cell.com